BioSpace News Archive

The study evaluated CTX-1301, Cingulate’s proprietary, first-line stimulant medication for the treatment of ADHD, utilizing an innovative, proprietary timed release technology OralogiK developed by CTx’s partner BDD.

O’Brien joins Relay Therapeutics with significant strategic human resources experience in the life sciences industry.

Dr. Burgess joins from Bristol-Myers Squibb, where he was senior vice president of development across multiple therapeutic areas.

Luba Greenwood brings to IRX a wealth of pharmaceutical and biotechnology industry experience.

There were no treatment-related serious adverse events after 15 months.

The new clinical data, (conducted under GCP principles) from 149 adult and paediatric patients has shown unique results for the first time, with 36,2% of the patients having a complete prevention of oral mucositis during cancer therapy.

[15-November-2017] MADRID, November 15, 2017 /PRNewswire/ -- PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre(R) (PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without

The OLE study offers patients an opportunity to receive repeat injections of Ampion after they have completed the pivotal clinical trial.

Combining the industry’s best respirator fit test with industry-first features, the new PortaCount platform is designed to provide intelligent fit test solutions across your entire respiratory protection program.

The impact on patient outcomes has consistently been positive.